Annexon develops targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases, with programs built around C1q and the classical complement pathway. Company news centers on clinical and regulatory progress for vonaprument in geographic atrophy, tanruprubart in Guillain-Barré syndrome, and ANX1502 as an oral C1 inhibitor for autoimmune disease.
Recurring updates also include quarterly financial results, research and development spending, cash runway disclosures, investor conference presentations, key opinion leader events, and equity inducement grants under Nasdaq rules. The company’s announcements connect pipeline progress with its balance sheet and public-company governance activity.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, announced that CEO Douglas Love will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 1:30 p.m. ET. This event will showcase Annexon's efforts in developing a new class of complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders. A live webcast will be available on the company's website, with a replay accessible for 30 days post-event.
Annexon focuses on therapies targeting the classical complement pathway, a key immune system mechanism. The company is advancing a pipeline of product candidates and expects to release clinical data throughout 2023.
Annexon, Inc. (Nasdaq: ANNX) announced its progress in clinical trials and financial results for 2022, highlighting its commitment to developing complement therapies. The company reported cash and equivalents of $242.7 million as of December 31, 2022, providing a runway into 2025. Significant milestones include anticipated mid-2023 data from the Phase 2 trial of ANX007 for geographic atrophy and ongoing trials for ANX1502, focusing on autoimmune conditions. R&D expenses were $112.5 million for 2022, with a net loss of $141.9 million. The company remains optimistic about its pipeline and future developments.
Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), is set to participate in the 43rd Annual Cowen Healthcare Conference on March 6, 2023, at 1:30 p.m. ET in Boston. CEO Douglas Love will engage in a fireside chat during the event. Interested parties can access the live webcast on Annexon's Investors page, with a replay available for 30 days post-event. Annexon focuses on creating innovative complement medicines aimed at treating autoimmune, neurodegenerative, and ophthalmic disorders, and is advancing a diversified pipeline with clinical data expected in 2023 and beyond.